S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ASRT

Assertio (ASRT) Stock Price, News & Analysis

$0.96
-0.03 (-3.10%)
(As of 05:41 PM ET)
Today's Range
$0.95
$1.02
50-Day Range
$0.79
$1.14
52-Week Range
$0.77
$8.01
Volume
930,789 shs
Average Volume
1.12 million shs
Market Capitalization
$91.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Assertio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
473.3% Upside
$5.50 Price Target
Short Interest
Bearish
11.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Assertio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$11,481 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.04) to $0.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

736th out of 938 stocks

Pharmaceutical Preparations Industry

335th out of 425 stocks

ASRT stock logo

About Assertio Stock (NASDAQ:ASRT)

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

ASRT Stock Price History

ASRT Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Q4 2023 Assertio Holdings Inc Earnings Call
Recap: Assertio Holdings Q4 Earnings
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Assertio: Q4 Earnings Snapshot
ASRT Mar 2024 4.500 call
Assertio Holdings's Earnings: A Preview
Assertio 24 Hour Deadline Alert
Assertio 48 Hour Deadline Alert
Assertio Shareholder Notice
See More Headlines
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ASRT
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+473.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-331,940,000.00
Net Margins
-218.28%
Pretax Margin
-167.07%

Debt

Sales & Book Value

Annual Sales
$152.07 million
Cash Flow
$0.69 per share
Book Value
$1.46 per share

Miscellaneous

Free Float
87,495,000
Market Cap
$91.13 million
Optionable
Optionable
Beta
0.96
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

ASRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Assertio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings
or view top-rated stocks.

What is Assertio's stock price target for 2024?

1 equities research analysts have issued 12-month price objectives for Assertio's stock. Their ASRT share price targets range from $4.00 to $7.00. On average, they anticipate the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 473.3% from the stock's current price.
View analysts price targets for ASRT
or view top-rated stocks among Wall Street analysts.

How have ASRT shares performed in 2024?

Assertio's stock was trading at $1.07 on January 1st, 2024. Since then, ASRT shares have decreased by 10.3% and is now trading at $0.9593.
View the best growth stocks for 2024 here
.

Are investors shorting Assertio?

Assertio saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 10,730,000 shares, an increase of 9.5% from the February 29th total of 9,800,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the short-interest ratio is currently 9.8 days.
View Assertio's Short Interest
.

When is Assertio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ASRT earnings forecast
.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) released its earnings results on Thursday, November, 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.12. The firm had revenue of $25.47 million for the quarter, compared to analyst estimates of $22.04 million. Assertio had a negative net margin of 218.28% and a positive trailing twelve-month return on equity of 6.30%. During the same period last year, the company posted ($0.36) EPS.

What ETF holds Assertio's stock?

Hartford Multifactor Small Cap ETF holds 43,843 shares of ASRT stock, representing 0.64% of its portfolio.

What guidance has Assertio issued on next quarter's earnings?

Assertio issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110.0 million-$125.0 million, compared to the consensus revenue estimate of $160.6 million.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

Who are Assertio's major shareholders?

Assertio's stock is owned by a number of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (8.05%), Armistice Capital LLC (6.13%), Vanguard Group Inc. (5.15%), Vanguard Group Inc. (5.15%), Goldman Sachs Group Inc. (1.25%) and Goldman Sachs Group Inc. (1.25%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Heather L Mason, James L Tyree, Paul Schwichtenberg, Sam Schlessinger and William Mckee.
View institutional ownership trends
.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASRT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners